Recurrence And Progression According To Stage At Re-Tur In T1g3 Bladder Cancer Patients Treated With Bcg: Not As Bad As Previously Thought

You have accessJournal of UrologyBladder Cancer: Non-invasive III1 Apr 2017PD48-07 RECURRENCE AND PROGRESSION ACCORDING TO STAGE AT RE-TUR IN T1G3 BLADDER CANCER PATIENTS TREATED WITH BCG: NOT AS BAD AS PREVIOUSLY THOUGHT Joan Palou, Paolo Gontero, Francesca Pisano, steven Joniau, Kathy Vander Eeckt, Marco Oderda, Vincenzo Serretta, Stephane Larrè, Savino Di Stasi, Bas Van Rhijn, Alfred J Witjes, Anne Grotenhuis, Renzo Colombo, Alberto Briganti, Amrek Babjuk, Viktor Soukup, Per Uno Malmstrom, Jaques Irani, Nuria Malats, Jack Baniel, Roy Mano, Tommaso Cai, Eugene Cha, Peter Ardelt, John Varkarakis, Riccardo Bartoletti, Martin Sphan, Guido Dalbagni, Shahrokh F Shariat, Evangelous Xylinas, R Jeffrey Karnes, and Richard Sylvester Joan PalouJoan Palou More articles by this author , Paolo GonteroPaolo Gontero More articles by this author , Francesca PisanoFrancesca Pisano More articles by this author , steven Joniausteven Joniau More articles by this author , Kathy Vander EecktKathy Vander Eeckt More articles by this author , Marco OderdaMarco Oderda More articles by this author , Vincenzo SerrettaVincenzo Serretta More articles by this author , Stephane LarrèStephane Larrè More articles by this author , Savino Di StasiSavino Di Stasi More articles by this author , Bas Van RhijnBas Van Rhijn More articles by this author , Alfred J WitjesAlfred J Witjes More articles by this author , Anne GrotenhuisAnne Grotenhuis More articles by this author , Renzo ColomboRenzo Colombo More articles by this author , Alberto BrigantiAlberto Briganti More articles by this author , Amrek BabjukAmrek Babjuk More articles by this author , Viktor SoukupViktor Soukup More articles by this author , Per Uno MalmstromPer Uno Malmstrom More articles by this author , Jaques IraniJaques Irani More articles by this author , Nuria MalatsNuria Malats More articles by this author , Jack BanielJack Baniel More articles by this author , Roy ManoRoy Mano More articles by this author , Tommaso CaiTommaso Cai More articles by this author , Eugene ChaEugene Cha More articles by this author , Peter ArdeltPeter Ardelt More articles by this author , John VarkarakisJohn Varkarakis More articles by this author , Riccardo BartolettiRiccardo Bartoletti More articles by this author , Martin SphanMartin Sphan More articles by this author , Guido DalbagniGuido Dalbagni More articles by this author , Shahrokh F ShariatShahrokh F Shariat More articles by this author , Evangelous XylinasEvangelous Xylinas More articles by this author , R Jeffrey KarnesR Jeffrey Karnes More articles by this author , and Richard SylvesterRichard Sylvester More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2355AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The goals of transurethral resection of a bladder tumour (TUR) are to completely resect the lesions and to make a correct diagnosis in order to adequately stage the patient. Persistent disease after TUR is not uncommon and is the reason why re-TUR is recommended in T1G3 patients. When there is T1 tumour in the re-TUR specimen, very high risks of progression (82%) have been reported1 and therefore cystectomy is considered to be mandatory. We analyse the tumour stage at re-TUR and the risk of recurrence, progression to muscle invasive disease and cancer specific mortality (CSM) in T1G3 patients treated with BCG. METHODS In our retrospective cohort of 2451 T1G3 patients initially treated with BCG, pathology results for 934 patients (38.1%) who underwent re-TUR are available. There was no residual disease in 267 patients (28.6%) and residual disease in 667 patients (71.4%): Ta in 378 (40.5%) and T1 in 289 (30.9%) patients. 310 patients (33.2%) received more than 6 instillations of BCG. Event rates in the 3 groups were compared using the chi-square statistic on 2 degrees of freedom RESULTS Table 1 shows the observed results with a median follow up of 5.2 years and a maximum follow up of 18.7 years. Similar trends were seen in both patients with and patients without muscle in the original TUR specimen. CONCLUSIONS Patients with T1G3 tumours treated with BCG and no residual disease or Ta tumour at re-TUR have better recurrence, progression and CSM rates than those with T1 tumour. The 25.3% progression rate of patients with T1 disease after re-TUR is far lower than that previously reported, with a CSM rate of 13.1%. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e903 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Joan Palou More articles by this author Paolo Gontero More articles by this author Francesca Pisano More articles by this author steven Joniau More articles by this author Kathy Vander Eeckt More articles by this author Marco Oderda More articles by this author Vincenzo Serretta More articles by this author Stephane Larrè More articles by this author Savino Di Stasi More articles by this author Bas Van Rhijn More articles by this author Alfred J Witjes More articles by this author Anne Grotenhuis More articles by this author Renzo Colombo More articles by this author Alberto Briganti More articles by this author Amrek Babjuk More articles by this author Viktor Soukup More articles by this author Per Uno Malmstrom More articles by this author Jaques Irani More articles by this author Nuria Malats More articles by this author Jack Baniel More articles by this author Roy Mano More articles by this author Tommaso Cai More articles by this author Eugene Cha More articles by this author Peter Ardelt More articles by this author John Varkarakis More articles by this author Riccardo Bartoletti More articles by this author Martin Sphan More articles by this author Guido Dalbagni More articles by this author Shahrokh F Shariat More articles by this author Evangelous Xylinas More articles by this author R Jeffrey Karnes More articles by this author Richard Sylvester More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...